Evidence map›Paper›PMID 24533272›Full record

ArticleInternational journal for parasitology. Drugs and drug resistance2012

Di-cationic arylimidamides act against Neospora caninum tachyzoites by interference in membrane structure and nucleolar integrity and are active against challenge infection in mice.

Michelle Schorer, Karim Debache, Fabienne Barna, Thierry Monney, Joachim Müller, David W Boykin, Chad E Stephens, Andrew Hemphill

Open access · goldAbstract read
In one paragraph

Article in International journal for parasitology. Drugs and drug resistance, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. NcPuf1 Is a Key Virulence Factor inPathogens (Basel, Switzerland) · 2020
    Article
  5. Article
  6. Review
  7. Article
  8. Drug target identification in protozoan parasites.Expert opinion on drug discovery · 2016
    Review
  9. Article
  10. Article
  11. Buparvaquone is active against Neospora caninum in vitro and in experimentally infected mice.International journal for parasitology. Drugs and drug resistance · 2015
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Expert opinion on therapeutic targets
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Michelle SchorerInstitute of Parasitology, Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Berne, Länggassstrasse 122, CH-3012 Bern, Switzerland.
Karim DebacheInstitute of Parasitology, Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Berne, Länggassstrasse 122, CH-3012 Bern, Switzerland.
Fabienne BarnaInstitute of Parasitology, Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Berne, Länggassstrasse 122, CH-3012 Bern, Switzerland.
Thierry MonneyInstitute of Parasitology, Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Berne, Länggassstrasse 122, CH-3012 Bern, Switzerland.
Joachim MüllerInstitute of Parasitology, Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Berne, Länggassstrasse 122, CH-3012 Bern, Switzerland.
David W BoykinDepartment of Chemistry, Georgia State University, P.O. Box 4098, Atlanta, GA 30302-4098, USA.
Chad E StephensDepartment of Chemistry and Physics, Augusta State University, Augusta, GA 30904-2200, USA.
Andrew HemphillInstitute of Parasitology, Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Berne, Länggassstrasse 122, CH-3012 Bern, Switzerland.
University of Bern · CHGeorgia State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neospora caninum is considered to be the main cause of bovine abortion in Europe and the USA, leading to considerable financial impact. Losses are caused directly by abortions or indirectly through breeding of calves with impaired viability. Due to the lack of effective chemotherapy against bovine neosporosis, there is a need to develop new anti-protozoal compounds, which would either eliminate the parasite or avoid its transmission. In order to identify compounds of interest, the in vitro activities of 41 di-cationic pentamidine derivatives were studied employing a transgenic N. caninum clone expressing beta-galactosidase as a reporter gene. The arylimidamide DB745, previously shown to be highly active against Leishmania donovani in vitro and in vivo, appeared as the most promising compound, with an IC50 of 80 nM in 3-day growth assays and severely affecting both host cell invasion as well as intracellular proliferation. TEM of intracellular tachyzoites identified distinct alterations related to the nucleolus and the nuclear and cellular membrane. Long-term growth assays showed that DB745 acted parasiticidal upon the Nc-Liv isolate, but not against the Nc-1 isolate of N. caninum. In vivo studies in N. caninum (Nc-1 isolate) infected mice showed that daily intraperitoneal application of DB745 for a period of 14 days resulted in a decreased number of clinically affected animals, and lower cerebral parasite burdens in DB745-treated mice compared to non-treated mice. These results illustrate the potential of dicationic arylimidamides for the treatment of N. caninum infections.

Indexed as

ArylimidamidesInvasionIn vivo activityMembrane integrityNeospora caninumNucleolusProliferationTachyzoites

Identifiers

PMID24533272
PMCPMC3862485
OpenAlexW2002291823

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.